Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 329

1.

Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.

Gaspar PA, Bustamante ML, Silva H, Aboitiz F.

J Neurochem. 2009 Nov;111(4):891-900. doi: 10.1111/j.1471-4159.2009.06325.x. Epub 2009 Aug 4. Review.

2.

From glutamatergic dysfunction to cognitive impairment: boundaries in the therapeutic of the schizophrenia.

Gaspar PA, Bustamante ML, Rojo LE, Martinez A.

Curr Pharm Biotechnol. 2012 Jun;13(8):1543-8. Review.

PMID:
22283759
3.
4.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

5.

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications.

Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J.

Clin Neuropharmacol. 2001 Jan-Feb;24(1):43-9. Review.

PMID:
11290881
6.

Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Muller N, Schwarz M.

Neurotox Res. 2006 Oct;10(2):131-48. Review.

PMID:
17062375
7.

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A.

Clin Ther. 2005;27 Suppl A:S16-24. Review.

PMID:
16198197
8.

Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.

Heresco-Levy U.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1113-23. Review.

PMID:
14642971
9.

Pathophysiologically based treatment interventions in schizophrenia.

Lewis DA, Gonzalez-Burgos G.

Nat Med. 2006 Sep;12(9):1016-22. Review.

PMID:
16960576
10.
11.

Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development.

Müller N.

Expert Opin Ther Targets. 2008 Dec;12(12):1497-507. doi: 10.1517/14728220802507852 . Review.

PMID:
19007319
12.

Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.

Stone JM.

Curr Pharm Des. 2009;15(22):2594-602. Review.

PMID:
19689330
13.

The glutamatergic dysfunction hypothesis for schizophrenia.

Coyle JT.

Harv Rev Psychiatry. 1996 Jan-Feb;3(5):241-53. Review.

PMID:
9384954
14.

Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.

Lewis DA, Moghaddam B.

Arch Neurol. 2006 Oct;63(10):1372-6. Review.

PMID:
17030651
15.

Glutamate as a therapeutic target in psychiatric disorders.

Javitt DC.

Mol Psychiatry. 2004 Nov;9(11):984-97, 979. Review.

PMID:
15278097
16.

Glutamatergic theories of schizophrenia.

Javitt DC.

Isr J Psychiatry Relat Sci. 2010;47(1):4-16. Review.

17.

Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.

de Bartolomeis A, Fiore G, Iasevoli F.

Curr Pharm Des. 2005;11(27):3561-94. Review.

PMID:
16248808
18.

The acute effects of NMDA antagonism: from the rodent to the human brain.

Gunduz-Bruce H.

Brain Res Rev. 2009 May;60(2):279-86. doi: 10.1016/j.brainresrev.2008.07.006. Epub 2008 Jul 30. Review.

PMID:
18703087
19.

Direct and indirect modulation of the N-methyl D-aspartate receptor.

Marino MJ, Conn PJ.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):1-16. Review.

PMID:
12769631
20.
Items per page

Supplemental Content

Write to the Help Desk